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Abstract
Background—The use of docetaxel prolongs survival for patients with castrate resistant prostate
cancer (CRPC). Inhibition of vascular endothelial growth factor (VEGF) with bevacizumab may
further enhance the anti-tumor effect of docetaxel and estramustine in patients with CRPC.
Patients and Methods—This cooperative group trial enrolled men with CRPC. Patients
received oral estramustine 280 mg three times per day on days 1-5 of every cycle, with 70 mg/m2
of docetaxel and bevacizumab at 15 mg/kg on day 2, every three weeks. PSA values were
monitored every cycle and imaging was performed every 3 cycles. The primary endpoint was
progression free survival (PFS) with safety, prostate specific antigen decline, measurable disease
response, and overall survival secondary objectives.
Results—Seventy-nine patients were enrolled; 77 received a median of 8 cycles and were
evaluable. A 50% PSA decline was observed in 58 patients (75%). Twenty-three of 39 patients
with measurable disease had a partial response (59%) The median time of PFS was 8.0 months
with an overall median survival of 24 months. Neutropenia without fever (69%), fatigue (25%),
thrombosis\emboli (9%) were the most common severe toxicities. Twenty-four of 77 patients were
removed from protocol treatment due to disease progression, 35/77 for physician or patient
decision and 15 patients secondary to toxicity.
Conclusion—The combination of docetaxel, estramustine and bevacizumab was tolerable but
complicated by toxicity. Although progression free survival did not meet the desired endpoint,
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encouraging anti-tumor activity and overall survival was observed. Further phase III evaluation of
the role of bevacizumab in CRPC is ongoing.
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INTRODUCTION
Metastatic prostate cancer is often treated by castration which provides temporary palliation
of symptoms and control of tumor growth.1 In the past, treatment for patients with castrate
resistant prostate cancer (CRPC) was focused on palliative therapy, but the introduction of
docetaxel based therapies has led to survival improvement. The use of docetaxel has shown
a survival advantage over mitoxantrone and has become the standard for patients with
CRPC.2,3 The overall survival advantage of 2.9 months is modest and further therapies that
improve this survival of patients treated with docetaxel based therapies are needed.4
Prior to the completion of the phase III trials of docetaxel versus mitoxantrone, the Cancer
and Leukemia Group B (CALGB) developed a series of sequential studies to evaluate the
addition of novel agents to the docetaxel backbone. The addition of carboplatin was
tolerated but did increase the myelosuppression of the regimen without a clear signal of
increased activity.5 Exisulind which was thought to induce apoptosis in malignant cells was
also combined with docetaxel and estramustine.6 Significant morbidity was associated with
this combination without a substantial improvement in the efficacy.
Vascular endothelial growth factor (VEGF) is a glycoprotein important in promoting tumor
angiogenesis 7,8 and plays a critical role in the progression of human prostate cancer. Flk-1/
KDR receptors are expressed in human prostate cancer which correlates with higher grade
lesions and outcome.9 Expression of vascular endothelial growth factor (VEGF) is observed
in prostate tumors as well as in the plasma and urine of patients with metastatic disease with
increasing expression correlating with disease progression.10,11 Studies have shown that
plasma and urine VEGF levels in CRPC patients are independent predictors of survival.12,13
Bevacizumab, a humanized murine monoclonal antibody that neutralizes VEGF activity was
therefore felt to be a reasonable therapeutic approach for advanced prostate cancer. A single-
center study administering bevacizumab 10 mg/kg every 2 weeks in 15 patients with CRPC
was well tolerated. However, as expected with this class of agents, minimal evidence of
activity were observed with monotherapy.14 Evolving data in other cancers suggested that
the overall benefit of VEGF blockade is more apparent when bevacizumab is combined with
a cytotoxic agent. Based on the compelling in vivo data, the importance of circulating VEGF
levels in CRPC and safety of bevacizumab, a multi-institutional trial of docetaxel,
estramustine and bevacizumab was conducted.
PATIENTS AND METHODS
Patient Selection
This study was approved by the Executive Committee of the CALGB, and by the
Institutional Review Board of each participating site. All patients provided written, informed
consent. All patients were required to have evidence of metastatic prostate cancer despite
castrate levels of testosterone (≤ 50 ng/ml). Patients were required to have evidence of
progressive metastatic disease with documented measurable disease progression on cross-
sectional imaging, new lesions on bone scan, or two sequential rises in PSA with baseline
PSA being greater than 5 ng/ml. Anti-androgens and megestrol acetate were required to be
discontinued for at least 4 weeks prior to registration with evidence of progression noted
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after their discontinuation. All patients were required to continue luteinizing hormone
releasing hormone (LHRH) agonist if they have not had an orchiectomy. Patients were not
allowed to have received prior cytotoxic therapy or other anti-angiogenesis agents including
thalidomide. Patients were required to be at least 4 weeks from major surgery or radiation
therapy, and at least 8 weeks since radionuclide therapy. All patients had to have an Eastern
Cooperative Oncology Group (ECOG) performance status ≤ 2; no significant peripheral
neuropathy; and no prior myocardial infarction, deep venous thrombosis, pulmonary
embolus, or other major thromboembolic event within 1 year of entry. Patients requiring full
dose anti-coagulation were also excluded. Patients were required to have a granulocytes
>1500/μl, platelets > 100,000/μl, creatinine < 1.5 times the upper limit of normal (ULN),
bilirubin < ULN, AST < 1.5 times the ULN, and urinalysis ≤ 1+ protein on dipstick. Patients
receiving stable bisphosphonate therapy for at least four weeks prior to entry were allowed
to continue, but initiation of bisphosphonate therapy was not allowed.
Treatment and Evaluation
Therapy was based on 21 day cycles. Patients received 280 mg of estramustine phosphate
(Emcyt, Pharmacia Oncology, Peapack, NJ) TID on days 1-5, decadron 8 mg BID on days
1-3, docetaxel (Taxotere, Sanofi-Aventis, Bridgewater, NJ) 70 mg/m2 on day 2
intravenously over one hour, and bevacizumab (supplied by Genentech, distributed by NCI)
15 mg/kg intravenously administered after docetaxel on day 2. The first infusion of
bevacizumab was administered over 90 minutes, the second over 60 minutes, and the third
and subsequent doses were administered over 30 minutes if well tolerated. The dose was 5
mg/kg/week consistent with most other malignancies, and given every three weeks
coordinated with chemotherapy administration. Warfarin, 2 mg daily was encouraged but
not mandated as prophylaxis for thrombosis from estramustine, unless a contraindication
existed. Hematological growth factors were allowed per ASCO guidelines, but prophylactic
use was not allowed.
Patients were evaluated every cycle with a PSA, and every 3rd cycle with bone scans and CT
scans of the abdomen and pelvis. Patients were encouraged to have blood pressure
monitored weekly, and weekly blood counts were required. Liver function tests, including
bilirubin, transaminase levels and alkaline phosphatase, along with urinalysis were analyzed
prior to administration of the chemotherapy every cycle.
The therapy was held for ANC<1500/μl, platelets <100,000/μl with dose reduction to 75%
of the starting docetaxel dose upon recovery, or for any episode of febrile neutropenia. For
elevations of SGOT >1.5 ULN, the dose of docetaxel was reduced to 60 mg/m2, and for
bilirubin levels >1.5 ULN or SGOT >5 ULN, the docetaxel dose was held. When the
docetaxel dose was held, the estramustine and bevacizumab doses were also held. For grade
2 neurotoxicity, the estramustine was reduced by 50% and held with grade 3 toxicity. For
grade 3 neurotoxicity, the docetaxel was reduced to 75%. For persistant grade 3
neurotoxicity, the docetaxel was held. If chemotherapy was held >3 weeks, patients were
removed from protocol treatment. For thromboembolic events, once anticoagulated, patients
were allowed to continue on protocol with discontinuation of bevacizumab and
estramustine. For proteinuria >2+ on dipstick, a 24-hour urine protein measurement was
required, and if it showed >2000 mg/day of protein, bevacizumab was held.
Disease progression and response were based on the PSA working group Consensus
Criteria15 and RECIST criteria were used for patients with measurable disease. Bone scan
progression was defined as any new lesions.
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Statistical Design and Data Analysis
The primary endpoint of this study was time to progression. Progression-free survival (PFS)
was defined as the interval between treatment initiation and the date of progression or death,
whichever occurred first. Sample size computation was based on the primary endpoint. The
null hypothesis was that the median time to progression would be less than or equal to 11
months and the alternative hypothesis was that the median time to progression would be at
least as great as 16 months (45% increase). The target sample size was 79 assuming an
ineligibility rate of 10%. The normal approximation to the exact exponential test was used
for sample size computation and the following assumptions were made: a) type I error
rate=0.05, b) power=89% (type II error rate=11%), c) accrual rate of 4 patients/month over a
18-month accrual period), d) a 24-month follow-up period, and e) the time to progression
follows an exponential distribution. Under the alternative hypothesis, 55 progression events
were expected at the end of the trial.
Toxicity was an important secondary endpoint with a hypothesized null hypothesis that the
acceptable toxicity probability was ≤0.80 versus the alternative hypothesis that acceptable
toxicity probability was ≥0.90. Unacceptable toxicity was defined as death, grade 4 febrile
neutropenia or any serious grade 3 or grade 4 toxicity, excluding nausea, vomiting, alopecia
or hypersensitivity. For the purpose of this study, a “serious” toxicity was defined as cardiac,
thrombosis/embolism, or CNS hemorrhage/bleeding. Toxicity was monitored using a three-
stage design after 15, 35 and 72 patients were enrolled and received one full cycle of
therapy. This design had a type I error rate of 0.10 and a power of 89% based on binomial
simulations. The decision rules for continuation of accrual required at least 11 out of 15
patients, at least 27 out of 35 patients and at least 62 out of 72 did not experience
unacceptable toxicity.
Other endpoints considered were PSA progression-free survival (PSA PFS), overall
survival, duration of objective response and duration of PSA decline. PFS was defined as the
interval between treatment initiation and the date of any disease progression (bone, PSA
PFS, soft tissue), or clinical deterioration, or death, whichever occurred first. PSA PFS was
defined as time to first biochemical progression using the PSA consensus criteria or death,
whichever occurred first. Overall survival was defined as interval between treatment
initiation and the date of death. Duration of response was defined as the date of the first CR
or PR to the date that the patient had disease progression. Duration of PSA response was
interval between date from the first 50% decline in PSA to the date when the patient met the
criteria for disease progression. The 95% confidence interval for the objective response rate
was computed based on the binomial distribution. Overall survival, objective PFS, PSA PFS
and PFS distributions were estimated using the Kaplan-Meier product-limit method.16
As part of the quality assurance program of the CALGB, members of the Audit Committee
visit all participating institutions at least once every three years to review source documents.
The auditors verify compliance with federal regulations and protocol requirements in a
sample of protocols at each institution. On-site review of medical records was done on a
subgroup of 39 patients (49%) of the 79 patients under this study. Patient registration and
data collection were managed by the CALGB Statistical Center. Data quality assurance
included careful review of data by CALGB Statistical Center staff and by the study
chairperson. CALGB statisticians performed all statistical analyses.
RESULTS
Patient Characteristics
Seventy-nine patients were enrolled between October 2001 and November 2002; 77 patients
were eligible and assessable for treatment outcome (one patient did not meet eligibility
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criteria and one patient was registered but never received therapy). The median age was 69,
with a median PSA of 123 ng/ml (range 0.1-2231 ng/ml) (Table 1). The median time since
diagnosis was 4 years, with an overall range of 0-17 years. Eighty-six percent of the patients
had bone disease, with 19% having visceral involvement. Overall 51% of the patients had
measurable disease as defined by RECIST.
Study Treatment
The median number of cycles of therapy administered was 8 (range 1-30). Of the 77
evaluable patients, 24 (31%) came off therapy due to disease progression, 15 (19%) stopped
due to protocol defined toxicity, and 35 (45%) for physician or patient decision, but not
required by protocol. Three (4%) patients died while on therapy. Patients that stopped
therapy based on physician and patient decision (n=35), did not have protocol defined
disease progression but opted for a “treatment” break. Patients after such a break were not
allowed to resume protocol therapy, but could restart docetaxel based therapies with the
agreement of their physicians. Data detailing subsequent treatments were not prospectively
collected.
Dose reductions in one or more of the three drugs, in one or more cycles, occurred in 37/77
(48%) of the patients. The common reasons for reducing the dose of treatment included:
hematologic toxicity (12%), GI toxicity (6%), CNS toxicity (5%) and other (27%) such as
fatigue and depression. Some patients had more than one simultatneous requirement for dose
reduction.
Clinical Outcomes
Fifty eight of 77 patients (75%, 95% confidence interval(CI) of 64%-84%) had a ≥50%
post-therapy decline in PSA that was confirmed at least one month later. A waterfall plot of
the PSA decline at 12 weeks after the start of therapy is shown in figure 1.
The median time to PSA response was 1.4 months. The median time to PSA progression
was 9.2 months (95% CI=7.5-10.9 months). The median duration of PSA decline was 8.5
months (95% CI=6.1-9.8). Twenty three of 39 men with measurable disease (59%, 95%
CI=42%-74%) has a partial response by RECIST criteria and the median duration of
measurable disease response was 21.5 months (95%CI=14.6-26.7 months).
The median time to any progression for patients was 8.0 months (95% CI=5.9 to 9.5
months). Patients with measurable disease had a median time to measurable disease
progression of 16.5 months (95% CI=10.9-23.2 months). 75 patients have died. Sixty eight
of these patients (90.7%) have died of prostate cancer and the median follow-up time for the
surviving patients is 69 months. The median overall survival time is 24 months (95%
CI=20.3-26.5 months) (Figure 2).
Adverse Events
Table 2 presents adverse events that are probable, possible and definitely related to
treatment. Three patients died on study. One patient died of an infection without
neutropenia, one patient had a mesenteric vein thrombosis, and one patient had a bowel
perforation complicated by severe metabolic acidosis. Grade 3 or 4 leukopenia and
neutropenia occurred in 53% and 62% of the patients, respectively, however febrile
neutropenia only occurred in 3 patients (4%). Overall, severe (grade 3, 4 and 5) febrile
neutropenia, infection with and without neutropenia were observed in 17 (22%) patients.
Fatigue was common with 25% having severe grade 3 or 4 fatigue that required dose
reduction in 4 cases, delaying therapy in 2 cases and in at least 6 cases therapy was
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discontinued. The median onset of the severe fatigue was at 7 cycles. Seven patients (9%)
had thromboembolic complications. Four patients (5%) developed deep venous thrombosis
and three patients (4%) had pulmonary emboli which resulted in death of one patient. One
patient had a grade 4 cerebral hemorrhage in the left parietal lobe associated with mild
aphasia that partially recovered. Two patients had a grade 3 or 4 cerebral vascular accident
and one was associated with grade 3 hyponatremia with resolution of mental status changes
with treatment.
Low grade epistaxis occurred in 42% of the patients, one patient had grade 3 epistaxis and
two patients had grade 3 gastrointestinal bleed that were self limited. Mild hypertension
(grade 1 and 2) was seen in 11% of the patients and more severe (grade 3 or 4 hypertension)
was observed in 5% of the cases without serious complications. Low grade proteinuria was
seen in 20% of the patients but grade 3 or 4 proteinuria was only observed in one patient
after 22 cycles of therapy that improved after discontinuing bevacizumab.
DISCUSSION
The addition of bevacizumab to standard chemotherapy has significantly improved the
survival in colon cancer patients and data suggests that bevacizumab may play a similar role
in patients with CRPC. To further extend the regimen of docetaxel and estramustine tested
by the CALGB17, bevacizumab was added to evaluate the safety and clinical activity of this
combination. While studies now suggest that the addition of estramustine may add little
clinical benefit to Docetaxel, this study was designed and implemented prior to release of
this data. 2,3
The combination of estramustine, docetaxel and bevacizumab has encouraging anti-tumor
activity with 75% of the patients having a 50% or more post-therapy PSA decline and 59%
of patients with measurable disease achieving a complete or partial response. This is very
favorable when compared the results that have been observed in many docetaxel based trials
(Table 3). Nevertheless, progression free survival, which was the primary endpoint of the
study was 8.1 months and did not meet the specified study endpoint of 11 months. However,
the 11 month PFS was an ambitious goal and evolving information now question whether
PFS is an adequate endpoint in a non-randomized study.18 In addition, it should be noted
that most patients stopped therapy not for progression, but due to need for a break from
treatment, which would shorten an endpoint such as progression free survival. Similarly,
overall survival in a non-randomized study is difficult to interpret. However a median
survival of 24 months (95% CI—20.3-26.5 mo) which was observed with these patients
surpassed the survival that was observed in sequential clinical trials in a similar population
by the CALGB by adding carboplatin, or exisulind to the docetaxel and estramustine
backbone.5,6
Bevacizumab can be added to the docetaxel and estramustine backbone safely, but is
associated with some increase in toxicity. Neutropenia was observed in 69% of the patients
which is two to three times higher than reported in the pivotal phase III studies with
docetaxel in CRPC. 2,3 Some of this frequency was due to obtaining blood counts on a
weekly basis, which was not done on other trials using docetaxel. However, this high level
of neutropenia did not translate into an increased proportion of patients developing febrile
neutropenia.
Bevacizumab induced grade 3 or 4 hypertension was seen in 5% of the cases but was
controlled. There were three treatment related deaths observed with the bevacizumab
combination. Deaths were attributed to an infection without neutropenia, a mesenteric vein
thrombosis, and bowel perforation. While the addition of bevacizumab appears to have
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contributed to the deaths of these patients, the mortality due to arterial thromboembolic
events or other causes does not appear to be higher than other studies in other tumors in an
elderly population treated with bevacizumab combinations.19 In addition, clearly the use of
estramustine may have contributed to some of these vascular related events. Thrombosis in
this trial is not different from other trials utilizing Estramustine.20 Overall the safety data
from this study would indicate that the addition of bevacizumab to docetaxel may modestly
increase the morbidity of the therapy in this elderly population and appropriate patient
selection is required to maintain safety when using bevacizumab.
In summary, this phase II trial has demonstrated that the addition of VEGF blockade with
bevacizumab to a docetaxel based regimen for the treatment of patients with metastatic
CRPC is feasible, well tolerated and may provide clinical benefit. The encouraging results
observed with this regimen have formed the basis for an intergroup, phase III, double blind
placebo controlled trial in castrate resistant prostate cancer that is comparing docetaxel and
prednisone with or without bevacizumab with a primary endpoint of overall survival. This
study is fully accrued, and the data is maturing.
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Waterfall plot of PSA responses at 12 weeks after initiating thereapy
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Survival curve of patients form date of enrollment
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Median Age 69 48-88
Race
    Caucasian 84%
    Black 9%
    Other or unknown 7%
Yrs since Diagnosis-Medians 4 0-17
Performance Status
            0-1 91%
             2 7%
Laboratory Values
Median Hemoglobin g/dl 12.7 8.1-14.8
        Interquartile Range         11.7-13.5
PSA 123 0.1-2231
        Interquartile Range         50-289
Alkaline Phosphatase IU/dl 182 41-5250
        Interquartile Range         98-361
Extent of Disease
Measurable Disease-Total 51%
    Lymph Nodes 41%
    Visceral disease 19%
    Soft tissue disease 18%
Bone disease 86%
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Table 3






90006 Picus et al.
Adverse Events Grade 3,4 or 5
Neutropenia 32% 12.5% 69%
Febrile neutropenia 3% 5% 4%
Infection - 13.6% 16%
Fatigue 5% - 25%
Pain - 11% 14%
Thrombosis\Embolism - 6% 9%
Hemorrhage - 4% 1%
Death, treatment related 0.3% 2.4% 3.8%
Clinical Outcomes
50% PSA Decline 32% 12.5% 75%
CR\PR –measurable disease 12% 17% 59%
Progression Free Survival ~8.2 months 6.3 months 8.0 months
Overall Survival 19.2 months 17.5 months 24 months
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